| Filed On | Filing |
|---|---|
| 23 Sep 2026 |
8-K: Other Events
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 20 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 20 Jul 2026 | 8-K: Regulation FD Disclosure |
| 14 Jul 2026 |
Form 4: Birx Deborah, Director
Gave up 14,041 shares to cover exercise price or tax ($59.8K) |
| 13 Jul 2026 | 8-K: Regulation FD Disclosure |
| 13 Jul 2026 | FORM S-8 |
| 24 Jun 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On June 24, 2026, the Board appointed Dr. Gilmer to serve on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as of June 24, 2026. |
| 23 Jun 2026 | 8-K: Other Events |
| 16 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 13 May 2026 | SCHEDULE 13D/A |
| 13 May 2026 | 10-Q |
| 13 May 2026 | 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more |
| 07 May 2026 | 8-K: Regulation FD Disclosure |
| 28 Apr 2026 |
Form 4: Gilmer Daniel B., Director
Granted 51,280 Stock Options (Right to Buy) |
| 28 Apr 2026 |
Form 3: Gilmer Daniel B., Director
No securities owned |
| 27 Apr 2026 | ARS |
| 27 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $1.2M, down 32% · say-on-pay vote |
Loading...
